Novavax (NVAX) Stock Price, News & Analysis

Company Overview

Novavax, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus. In addition to its COVID-19 vaccine, Novavax is advancing candidates targeting respiratory syncytial virus (RSV) and seasonal influenza. These programs leverage the same nanoparticle and adjuvant technologies to address ongoing unmet needs in respiratory infectious disease.

Novavax operates globally, with research and development facilities in North America and manufacturing partnerships in Europe, Asia and Africa. Collaborations with organizations such as the Serum Institute of India and SK bioscience support its ability to supply vaccines in diverse markets. This international footprint enables the company to respond rapidly to public health emergencies and to pursue broad distribution of its products.

Under the leadership of President and Chief Executive Officer John C. Jacobs, who joined the company in 2021, Novavax has focused on scaling manufacturing capacity and securing regulatory approvals for its vaccine candidates. The company’s executive team and board include experienced professionals from the vaccine and biopharmaceutical industries, guiding its efforts to expand the global reach of its proprietary vaccine platform.

Key Stats

• Today's Range: $8.08 to $8.67
• 50-Day Range: $6.56 to $9.71
• 52-Week Range: $5.01 to $15.22
• Volume: 6.16 million shs
• Average Volume: 6.50 million shs
• Market Capitalization: $1.39 billion
• P/E Ratio: 3.75
• Dividend Yield: N/A
• Price Target: $14.29
• Consensus Rating: Hold

Novavax Stock Analysis - MarketRank™

Novavax scored higher than 86% of companies evaluated by MarketBeat, and ranked 114th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Novavax has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 4 buy ratings, 1 hold rating, and 3 sell ratings.

Upside Potential

Novavax has a consensus price target of $14.29, representing about 66.9% upside from its current price of $8.56.

Amount of Analyst Coverage

Novavax has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Novavax are expected to grow in the coming year, from ($1.46) to $0.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novavax is 3.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 268.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novavax is 3.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 57.12.

Price to Earnings Growth Ratio

Novavax has a PEG Ratio of 0.11. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

27.28% of the float of Novavax has been sold short.

Short Interest Ratio / Days to Cover

Novavax has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Novavax has recently increased by 15.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Novavax does not currently pay a dividend.

Dividend Growth

Novavax does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.27

Percentage of Shares Shorted

27.28% of the float of Novavax has been sold short.

Short Interest Ratio / Days to Cover

Novavax has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Novavax has recently increased by 15.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.59

News Sentiment

Novavax has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Novavax this week, compared to 11 articles on an average week.

Search Interest

Only 35 people have searched for NVAX on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.

MarketBeat Follows

7 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novavax insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Novavax is held by insiders.

Percentage Held by Institutions

53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NVAX Stock Analysis - Frequently Asked Questions

How have NVAX shares performed this year?

Novavax's stock was trading at $8.04 at the beginning of the year. Since then, NVAX stock has increased by 6.5% and is now trading at $8.56.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) posted its earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.69. The business's quarterly revenue was down 42.4% on a year-over-year basis.
Read the conference call transcript.

When did Novavax's stock split?

Novavax shares reverse split on Friday, May 10th 2019.The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Novavax's major shareholders?

Novavax's top institutional shareholders include Shah Capital Management (7.11%), Geode Capital Management LLC (2.33%), Group One Trading LLC and TSP Capital Management Group LLC (0.86%). Insiders that own company stock include James F Young, Filip Dubovsky, Rachel K King and Gregory M Glenn.
View institutional ownership trends.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novavax investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Moderna (MRNA), Advanced Micro Devices (AMD), Pfizer (PFE) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NVAX
• CIK: 1000694
• Web: www.novavax.com
• Phone: (240) 268-2000
• Fax: 240-268-2100
• Employees: 1,990
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Novavax: $14.29
• High Price Target: $26.00
• Low Price Target: $6.00
• Potential Upside/Downside: +66.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.28
• Trailing P/E Ratio: 3.75
• Forward P/E Ratio: N/A
• P/E Growth: 0.11
• Net Income: -$187.50 million
• Net Margins: 39.20%
• Pretax Margin: 39.99%
• Return on Equity: -142.33%
• Return on Assets: 28.65%

Debt

• Debt-to-Equity Ratio: 5.93
• Current Ratio: 2.36
• Quick Ratio: 2.34

Sales & Book Value

• Annual Sales: $682.16 million
• Price / Sales: 2.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.89) per share
• Price / Book: -2.20

Miscellaneous

• Outstanding Shares: 162,420,000
• Free Float: 160,798,000
• Market Cap: $1.39 billion
• Optionable: Optionable
• Beta: 2.68